Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials [0.03%]
阿达芬肽治疗非酒精性脂肪肝病的疗效和安全性：随机对照试验的系统评价和.meta.分析
Mohamed Mahmoud Marey,Mohamed Belal,Abdelaziz A Awad et al.
Mohamed Mahmoud Marey et al.
Background: Non-alcoholic steatohepatitis (NASH) is an advanced subtype of non-alcoholic fatty liver disease (NAFLD). NASH prevalence is increasing exponentially and carries a high risk for disease progression, cirrhosis,...
Association between direct acting agents used for chronic hepatitis C virus infection and the occurrence of acute leukaemia - A disproportionality analysis [0.03%]
直接抗病毒药物治疗慢性丙型肝炎与急性白血病发病之间的关联性分析-倾向评分匹配的病例对照研究
Carole Scheifer,Bénédicte Lebrun-Vignes,Pascal Lebray et al.
Carole Scheifer et al.
Background and aims: A recent single-center study reported a significant increase in acute myeloid leukaemia (AML) cases, including mixed-phenotype acute leukaemia (MPAL), after exposure to direct acting agents (DAA). We ...
The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience [0.03%]
三十年来部分脾动脉栓塞的作用及演变：法国全国范围内90例患者的多中心回顾性单队列研究
Paul Leideck,Gisèle Nkontchou,Laure Elkrief et al.
Paul Leideck et al.
Background: Partial splenic embolization (PSE) has been proposed to treat the consequences of hypersplenism in the context of portal hypertension, especially thrombocytopenia. However, a high morbidity/mortality rate has ...
PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old [0.03%]
PBC中PPAR激动剂的研究进展：未来路在何方？如何选择新的和旧的药物？
Atsushi Tanaka,Christophe Corpechot
Atsushi Tanaka
The recent phase 3 trials of peroxisome proliferator-activated receptor (PPAR) agonists in primary biliary cholangitis (PBC) patients with incomplete response to ursodeoxycholic acid (UDCA) demonstrated very promising short-term biochemical...
Momina Javed,Amna Rizwan,Sabin Zafar
Momina Javed
Separating the effects of early and later life body mass index on liver diseases: A Mendelian randomization study [0.03%]
基于孟德尔随机化研究的身体质量指数的早期和晚期对肝脏疾病的影响分离研究表明
Feixiang Zhou,Xia Liu,Canyan Chang et al.
Feixiang Zhou et al.
Background and aim: The independent effects of childhood and adult body mass index (BMI) on non-alcoholic fatty liver disease (NAFLD), cirrhosis, and hepatocellular carcinoma (HCC) are lacking assessment. We aimed to sepa...
Diagnostic yield of repeat genetic testing in idiopathic chronic pancreatitis [0.03%]
特发性慢性胰腺炎患者重复进行基因检测的诊断价值
Solène Dermine,Emmanuelle Masson,Emmanuelle Girodon-Boulandet et al.
Solène Dermine et al.
Genetic testing is performed for unexplained pancreatitis. The aim of this study was to evaluate the diagnostic value of repeating genetic testing in idiopathic pancreatitis when new predisposing genes are identified. We investigated 330 pa...
CRISPR/Cas9 knockout of Ptgs2 promotes apoptosis of hepatic stellate cells [0.03%]
利用CRISPR/Cas9技术敲除Ptgs2促进肝星状细胞凋亡
Hongyu Zhou,Yongzhao Wang,Gaoli Zhu et al.
Hongyu Zhou et al.
PPARβ/δ as a promising molecular drug target for liver diseases: A focused review [0.03%]
PPARβ/δ作为治疗肝病的分子药物靶点的研究进展及展望
Xin Meng,Lin Wang,Yan-Chao Du et al.
Xin Meng et al.
Various liver diseases pose great threats to humans. Although the etiologies of these liver diseases are quite diverse, they share similar pathologic phenotypes and molecular mechanisms such as oxidative stress, lipid and glucose metabolism...